Jennifer Grandis, MD
American Cancer Society Professor
Otolaryngology
School of Medicine

Prior to joining UCSF, Dr. Grandis was the UPMC Endowed Chair in Head and Neck Cancer Surgical Research and Distinguished Professor of Otolaryngology and Pharmacology and Chemical Biology at the University of Pittsburgh. She led the Head and Neck Cancer Program and was the Vice Chair for Research in the Department of Otolaryngology.

Dr. Grandis’s research focuses on the signal transduction in head and neck squamous cell carcinoma (HNSCC) development and progression with the ultimate goal of targeting key pathways for therapeutic benefit. By taking key findings from the clinic and investigating mechanisms in a series of preclinical models, as well as developing novel therapeutic approaches in the laboratory and carrying out innovative clinical trials that employ these treatment strategies.

Dr. Grandis is an American Cancer Society Clinical Research Professor, and a member of the American Society for Clinical Investigation, the American Association of Physicians and the Institute of Medicine of the National Academies. She has published over 260 peer-reviewed articles. She has also contributed to more than 50 review articles and book chapters.

Research: Dr. Grandis's is dedicated to increasing our understanding of the genetic and epigenetic alterations in the upper aerodigestive tract mucosa, which mediate head and neck squamous cell carcinoma (HNSCC) progression. The overall goal is to identify predictive biomarkers, which can serve to select patients for therapies, including molecular targeting approaches. Translational resources developed to support projects include a large collection of patient-derived xenografts (PDXs) and tissue microarrays of over 500 human HNSCCs linked to a professionally curated clinical and pathologic database that includes information on treatment and survival. To date, the have examined the role of the epidermal growth factor receptor (EGFR), it’s ligands coordinate activation of STAT3 (signal transducer and activator of transcription) in head and neck carcinogenesis. Cumulative evidence from her laboratory suggests that TGF-?lpha/EGFR autocrine signaling leading to STAT3 activation is as early event in head and neck carcinogenesis. Strategies aimed at blocking the ligand, receptor or signaling protein demonstrated anti-tumor efficacy in preclinical models. Based on these promising results, they completed a Phase I clinical trial to investigate the toxicity and biologic effects of EGFR antisense gene therapy and a Phase II study was recently closed to accrual. They have developed STAT3 targeting strategies using a decoy oligonucleotide approach and early phase clinical testing demonstrated feasibility without toxicity. Ongoing studies are aimed at identifying the targetable genetic alterations in these cancers with the goal of designing precision medicine approaches. Emerging targets include activating mutations of the PI3K signaling pathway, primarily in HNSCC linked to HPV infection and mutation or promoter hypermethylation of selected PTPRs, which lead to STAT3 activation.

Specialty: General Otolaryngology

Expertise: Clinical and translational research

Professional Interests: Head and neck cancer, signal transduction, precision medicine, experimental therapeutics, preclinical cancer models, receptor crosstalk

Education and Training:

• Medical School: University of Pittsburgh School of Medicine, Pittsburgh, PA
• Internship: University of Pittsburgh School of Medicine, Pittsburgh, PA
• Residency: University of Pittsburgh School of Medicine, Pittsburgh, PA
• Fellowship: University of Pittsburgh School of Medicine, Pittsburgh, PA – Infectious Disease

• To Tip or Not to Tip: A New Combination for Precision Medicine in Head and Neck Cancer.
  Cancer research 2023 Lee RH, Johnson DE, Grandis JR
• New insights into RAS in head and neck cancer.
  Biochimica et biophysica acta. Reviews on cancer 2023 Jagadeeshan S, Novoplansky OZ, Cohen O, Kurth I, Hess J, Rosenberg AJ, Grandis JR, Elkabets M
• Mutated HRAS Activates YAP1-AXL Signaling to Drive Metastasis of Head and Neck Cancer.
  Cancer research 2023 Jagadeeshan S, Prasad M, Badarni M, Ben-Lulu T, Liju VB, Mathukkada S, Saunders C, Shnerb AB, Zorea J, Yegodayev KM, Wainer M, Vtorov L, Allon I, Cohen O, Gausdal G, Friedmann-Morvinski D, Cheong SC, …
• Therapeutic implications of transcriptomics in head and neck cancer patient-derived xenografts.
  PloS one 2023 Lee RH, Roy R, Li H, Hechmer A, Zhu TR, Izgutdina A, Olshen AB, Johnson DE, Grandis JR
• Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2023 Mascarella MA, Olonisakin TF, Rumde P, Vendra V, Nance MA, Kim S, Kubik MW, Sridharan SS, Ferris RL, Fenton MJ, Clayburgh DR, Ohr JP, Joyce SC, Sen M, Herman JG, Grandis JR, Zandberg DP, Duvvuri U
• Author Correction: Head and neck squamous cell carcinoma.
  Nature reviews. Disease primers 2023 Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR
• Transcription Factors and Cancer: Approaches to Targeting.
  Cancer journal (Sudbury, Mass.) 2023 Shiah JV, Johnson DE, Grandis JR
• The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancer.
  Advances in biological regulation 2022 VanLandingham NK, Nazarenko A, Grandis JR, Johnson DE
• STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Qureshy Z, Li H, Zeng Y, Rivera J, Cheng N, Peterson CN, Kim MO, Ryan WR, Ha PK, Bauman JE, Wang SJ, Long SR, Johnson DE, Grandis JR
• Emerging tyrosine kinase inhibitors for head and neck cancer.
  Expert opinion on emerging drugs 2022 Long Z, Grandis JR, Johnson DE
• Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.
  Cancer research 2022 Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR
• Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.
  Cancer research 2022 Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR
• The contemporary management of cancers of the sinonasal tract in adults.
  CA: a cancer journal for clinicians 2022 Thawani R, Kim MS, Arastu A, Feng Z, West MT, Taflin NF, Thein KZ, Li R, Geltzeiler M, Lee N, Fuller CD, Grandis JR, Floudas CS, Heinrich MC, Hanna E, Chandra RA
• Gender Equity in Science and Medicine: Breaking the Impasse.
  Cancer discovery 2022 Grandis JR
• Networking practices and gender inequities in academic medicine: Women's and men's perspectives.
  EClinicalMedicine 2022 Murphy M, Callander JK, Dohan D, Grandis JR
• NSAIDs Overcome PIK3CA Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models.
  Cancers 2022 Li H, Peyser ND, Zeng Y, Ha PK, Johnson DE, Grandis JR
• Mentoring Relationships and Gender Inequities in Academic Medicine: Findings From a Multi-Institutional Qualitative Study.
  Academic medicine : journal of the Association of American Medical Colleges 2022 Murphy M, Record H, Callander JK, Dohan D, Grandis JR
• Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.
  The Journal of clinical investigation 2021 Jin N, Keam B, Cho J, Lee MJ, Kim HR, Torosyan H, Jura N, Ng PK, Mills GB, Li H, Zeng Y, Barbash Z, Tarcic G, Kang H, Bauman JE, Kim MO, VanLandingham NK, Swaney DL, Krogan NJ, Johnson DE, Grandis JR
• Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer.
  JCI insight 2021 Bouhaddou M, Lee RH, Li H, Bhola NE, O'Keefe RA, Naser M, Zhu TR, Nwachuku K, Duvvuri U, Olshen AB, Roy R, Hechmer A, Bolen J, Keysar SB, Jimeno A, Mills GB, Vandenberg S, Swaney DL, Johnson DE, …
• Head and Neck Cancer among American Indian and Alaska Native Populations in California, 2009-2018.
  Cancers 2021 Warren BR, Grandis JR, Johnson DE, Villa A
• A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity.
  Science (New York, N.Y.) 2021 Swaney DL, Ramms DJ, Wang Z, Park J, Goto Y, Soucheray M, Bhola N, Kim K, Zheng F, Zeng Y, McGregor M, Herrington KA, O'Keefe R, Jin N, VanLandingham NK, Foussard H, Von Dollen J, Bouhaddou M, Jimenez…
• Paradigm shift in the pathogenesis and treatment of oral cancer and other cancers focused on the oralome and antimicrobial-based therapeutics.
  Periodontology 2000 2021 Radaic A, Ganther S, Kamarajan P, Grandis J, Yom SS, Kapila YL
• Treatment of Fanconi Anemia-Associated Head and Neck Cancer: Opportunities to Improve Outcomes.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Lee RH, Kang H, Yom SS, Smogorzewska A, Johnson DE, Grandis JR
• Women's Experiences of Promotion and Tenure in Academic Medicine and Potential Implications for Gender Disparities in Career Advancement: A Qualitative Analysis.
  JAMA network open 2021 Murphy M, Callander JK, Dohan D, Grandis JR
• Caspase-8 mutations associated with head and neck cancer differentially retain functional properties related to TRAIL-induced apoptosis and cytokine induction.
  Cell death & disease 2021 Cui Z, Dabas H, Leonard BC, Shiah JV, Grandis JR, Johnson DE
• PD-L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance.
  Head & neck 2021 Bhola NE, Njatcha C, Hu L, Lee ED, Shiah JV, Kim MO, Johnson DE, Grandis JR
• Correction: Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Wechsler EI, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, Grandis JR
• PD-1+CXCR5-CD4+ Th-CXCL13 cell subset drives B cells into tertiary lymphoid structures of nasopharyngeal carcinoma.
  Journal for immunotherapy of cancer 2021 Li JP, Wu CY, Chen MY, Liu SX, Yan SM, Kang YF, Sun C, Grandis JR, Zeng MS, Zhong Q
• IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer.
  Cancers 2021 Badarni M, Prasad M, Golden A, Bhattacharya B, Levin L, Yegodayev KM, Dimitstein O, Joshua BZ, Cohen L, Khrameeva E, Kong D, Porgador A, Braiman A, Grandis JR, Rotblat B, Elkabets M
• Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.
  Nature communications 2021 Wang Z, Goto Y, Allevato MM, Wu VH, Saddawi-Konefka R, Gilardi M, Alvarado D, Yung BS, O'Farrell A, Molinolo AA, Duvvuri U, Grandis JR, Califano JA, Cohen EEW, Gutkind JS
• Clinical trials optimizing investigator and self-collection of buccal cells for RNA yield.
  Laryngoscope investigative otolaryngology 2021 Geiger JL, Cedars ED, Zang Y, Normolle DP, Li H, Grandis JR, Centuori S, Johnson DE, Bauman JE
• Head and neck squamous cell carcinoma.
  Nature reviews. Disease primers 2020 Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR
• STAT3 decoy oligonucleotide-carrying microbubbles with pulsed ultrasound for enhanced therapeutic effect in head and neck tumors.
  PloS one 2020 Ramasamy T, Chen X, Qin B, Johnson DE, Grandis JR, Villanueva FS
• Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense Oligonucleotides.
  Molecular cancer therapeutics 2020 Shiah JV, Grandis JR, Johnson DE
• CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus-Associated Head and Neck Cancers.
  Molecular cancer research : MCR 2020 Cui Z, Kang H, Grandis JR, Johnson DE
• Targeting the JAK/STAT pathway in solid tumors.
  Journal of cancer metastasis and treatment 2020 Qureshy Z, Johnson DE, Grandis JR
• Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer.
  Cancers 2020 Bauman JE, Ohr J, Gooding WE, Ferris RL, Duvvuri U, Kim S, Johnson JT, Soloff AC, Wallweber G, Winslow J, Gaither-Davis A, Grandis JR, Stabile LP
• Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck Cancer.
  Molecular cancer therapeutics 2020 Izumi H, Wang Z, Goto Y, Ando T, Wu X, Zhang X, Li H, Johnson DE, Grandis JR, Gutkind JS
• MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling.
  Life science alliance 2020 Ngan HL, Liu Y, Fong AY, Poon PHY, Yeung CK, Chan SSM, Lau A, Piao W, Li H, Tse JSW, Lo KW, Chan SM, Su YX, Chan JYK, Lau CW, Mills GB, Grandis JR, Lui VWY
• Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer.
  Biochimica et biophysica acta. Molecular cell research 2020 Lee MJ, Jin N, Grandis JR, Johnson DE
• Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance.
  PloS one 2020 O'Keefe RA, Bhola NE, Lee DS, Johnson DE, Grandis JR
• Targeting STAT3 in Cancer with Nucleotide Therapeutics.
  Cancers 2019 Lau YK, Ramaiyer M, Johnson DE, Grandis JR
• Gene targets of sulforaphane in head and neck squamous cell carcinoma.
  Molecular medicine reports 2019 Hu L, Li H, Lee ED, Grandis JR, Bauman JE, Johnson DE
• NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer.
  Advances in biological regulation 2019 Cai Y, Yousef A, Grandis JR, Johnson DE
• Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Duvvuri U, George J, Kim S, Alvarado D, Neumeister VM, Chenna A, Gedrich R, Hawthorne T, LaVallee T, Grandis JR, Bauman JE
• HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma.
  Scientific reports 2019 Meister KS, Godse NR, Khan NI, Hedberg ML, Kemp C, Kulkarni S, Alvarado D, LaVallee T, Kim S, Grandis JR, Duvvuri U
• ATR inhibition sensitizes HPV- and HPV+ head and neck squamous cell carcinoma to cisplatin.
  Oral oncology 2019 Leonard BC, Lee ED, Bhola NE, Li H, Sogaard KK, Bakkenist CJ, Grandis JR, Johnson DE
• Investigational multitargeted kinase inhibitors in development for head and neck neoplasms.
  Expert opinion on investigational drugs 2019 Sola AM, Johnson DE, Grandis JR
• Correction: Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.
  Cancer research 2019 Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR, Arteaga CL
• Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer.
  The Journal of experimental medicine 2019 Hedberg ML, Peyser ND, Bauman JE, Gooding WE, Li H, Bhola NE, Zhu TR, Zeng Y, Brand TM, Kim MO, Jordan RCK, VandenBerg S, Olivas V, Bivona TG, Chiosea SI, Wang L, Mills GB, Johnson JT, Duvvuri U, …
• APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma.
  Oncogene 2019 Cannataro VL, Gaffney SG, Sasaki T, Issaeva N, Grewal NKS, Grandis JR, Yarbrough WG, Burtness B, Anderson KS, Townsend JP
• An update: emerging drugs to treat squamous cell carcinomas of the head and neck.
  Expert opinion on emerging drugs 2018 Lee YS, Johnson DE, Grandis JR
• Analysis of oncogenic activities of protein kinase D1 in head and neck squamous cell carcinoma.
  BMC cancer 2018 Zhang L, Li Z, Liu Y, Xu S, Tandon M, Appelboom B, LaValle CR, Chiosea SI, Wang L, Sen M, Lui VWY, Grandis JR, Wang QJ
• Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation.
  Oncogene 2018 Frazier NM, Brand T, Gordan JD, Grandis J, Jura N
• Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.
  Cancer 2018 Bauman JE, Duvvuri U, Thomas S, Gooding WE, Clump DA, Karlovits B, Wehbe A, Miller FR, Kim S, Sen M, Heron DE, Grandis JR, Argiris A
• Multiple Routes to Oncogenesis Are Promoted by the Human Papillomavirus-Host Protein Network.
  Cancer discovery 2018 Eckhardt M, Zhang W, Gross AM, Von Dollen J, Johnson JR, Franks-Skiba KE, Swaney DL, Johnson TL, Jang GM, Shah PS, Brand TM, Archambault J, Kreisberg JF, Grandis JR, Ideker T, Krogan NJ
• STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer.
  Molecular cancer therapeutics 2018 Njatcha C, Farooqui M, Kornberg A, Johnson DE, Grandis JR, Siegfried JM
• Biochemical Properties of a Decoy Oligodeoxynucleotide Inhibitor of STAT3 Transcription Factor.
  International journal of molecular sciences 2018 Lee DS, O'Keefe RA, Ha PK, Grandis JR, Johnson DE
• BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC.
  Cancer research 2018 Leonard B, Brand TM, O'Keefe RA, Lee ED, Zeng Y, Kemmer JD, Li H, Grandis JR, Bhola NE
• New Therapies in Head and Neck Cancer.
  Trends in cancer 2018 Santuray RT, Johnson DE, Grandis JR
• Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.
  Cancer research 2018 Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR
• Leveraging Genomics for Head and Neck Cancer Treatment.
  Journal of dental research 2018 Kemmer JD, Johnson DE, Grandis JR
• Targeting the IL-6/JAK/STAT3 signalling axis in cancer.
  Nature reviews. Clinical oncology 2018 Johnson DE, O'Keefe RA, Grandis JR
• High Content Imaging Assays for IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines.
  Methods in molecular biology (Clifton, N.J.) 2018 Johnston PA, Sen M, Hua Y, Camarco DP, Shun TY, Lazo JS, Grandis JR
• Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer.
  Seminars in radiation oncology 2018 Cho J, Johnson DE, Grandis JR
• The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Zhong Q, Liu ZH, Lin ZR, Hu ZD, Yuan L, Liu YM, Zhou AJ, Xu LH, Hu LJ, Wang ZF, Guan XY, Hao JJ, Lui VWY, Guo L, Mai HQ, Chen MY, Han F, Xia YF, Grandis JR, Zhang X, Zeng MS
• Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma.
  Head & neck 2017 Zhang H, Kim S, Chen Z, Nannapaneni S, Chen AY, Moore CE, Sica G, Mosunjac M, Nguyen MLT, D'Souza G, Carey TE, Peterson LA, McHugh JB, Graham M, Komarck CM, Wolf GT, Walline HM, Bellile E, Riddell J, …
• EGFR-targeted therapies in the post-genomic era.
  Cancer metastasis reviews 2017 Xu MJ, Johnson DE, Grandis JR
• The fourth edition of the head and neck World Health Organization blue book: editors' perspectives.
  Human pathology 2017 El-Naggar AK, Chan JKC, Takata T, Grandis JR, Slootweg PJ
• Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.
  Science translational medicine 2017 Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, Chen X, Vellano CP, Jeong KJ, Ng PK, Eterovic AKB, Bhola NH, Lu Y, Westin SN, Grandis JR, Lin SY, Scott KL, Peng G, Brugge J, Mills GB
• Mechanism of action of selective inhibitors of IL-6 induced STAT3 pathway in head and neck cancer cell lines.
  Journal of chemical biology 2017 Sen M, Johnston PA, Pollock NI, DeGrave K, Joyce SC, Freilino ML, Hua Y, Camarco DP, Close DA, Huryn DM, Wipf P, Grandis JR
• IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.
  Oral oncology 2017 Stabile LP, Egloff AM, Gibson MK, Gooding WE, Ohr J, Zhou P, Rothenberger NJ, Wang L, Geiger JL, Flaherty JT, Grandis JR, Bauman JE
• TMEM16A/ANO1 suppression improves response to antibody-mediated targeted therapy of EGFR and HER2/ERBB2.
  Genes, chromosomes & cancer 2017 Kulkarni S, Bill A, Godse NR, Khan NI, Kass JI, Steehler K, Kemp C, Davis K, Bertrand CA, Vyas AR, Holt DE, Grandis JR, Gaither LA, Duvvuri U
• Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer.
  JCI insight 2017 Bauman JE, Duvvuri U, Gooding WE, Rath TJ, Gross ND, Song J, Jimeno A, Yarbrough WG, Johnson FM, Wang L, Chiosea S, Sen M, Kass J, Johnson JT, Ferris RL, Kim S, Hirsch FR, Ellison K, Flaherty JT, …
• Nonpromoter methylation of the CDKN2A gene with active transcription is associated with improved locoregional control in laryngeal squamous cell carcinoma.
  Cancer medicine 2017 Ben-Dayan MM, Ow TJ, Belbin TJ, Wetzler J, Smith RV, Childs G, Diergaarde B, Hayes DN, Grandis JR, Prystowsky MB, Schlecht NF
• Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations.
  Nature communications 2017 Li YY, Chung GT, Lui VW, To KF, Ma BB, Chow C, Woo JK, Yip KY, Seo J, Hui EP, Mak MK, Rusan M, Chau NG, Or YY, Law MH, Law PP, Liu ZW, Ngan HL, Hau PM, Verhoeft KR, Poon PH, Yoo SK, Shin JY, Lee SD, …
• Cancer genomics: Spot the difference.
  Nature 2017 Peyser ND, Grandis JR
• Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, Grandis JR
• Head and neck cancer in 2016: A watershed year for improvements in treatment?
  Nature reviews. Clinical oncology 2016 Algazi AP, Grandis JR
• Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer.
  PloS one 2016 Peyser ND, Pendleton K, Gooding WE, Lui VW, Johnson DE, Grandis JR
• Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation.
  Cancer chemotherapy and pharmacology 2016 Kiesel BF, Parise RA, Guo J, Huryn DM, Johnston PA, Colombo R, Sen M, Grandis JR, Beumer JH, Eiseman JL
• Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer.
  Nature genetics 2016 Lesseur C, Diergaarde B, Olshan AF, Wünsch-Filho V, Ness AR, Liu G, Lacko M, Eluf-Neto J, Franceschi S, Lagiou P, Macfarlane GJ, Richiardi L, Boccia S, Polesel J, Kjaerheim K, Zaridze D, Johansson M, …
• A sensible approach to targeting STAT3-mediated transcription.
  Annals of translational medicine 2016 Bhola NE, Johnson DE, Grandis JR
• Treatment of head and neck cancer in the elderly.
  Expert opinion on pharmacotherapy 2016 Hartmann S, Grandis JR
• The non-coding landscape of head and neck squamous cell carcinoma.
  Oncotarget 2016 Zou AE, Zheng H, Saad MA, Rahimy M, Ku J, Kuo SZ, Honda TK, Wang-Rodriguez J, Xuan Y, Korrapati A, Yu V, Singh P, Grandis JR, King CC, Lippman SM, Wang XQ, Hinton A, Ongkeko WM
• HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Hartmann S, Bhola NE, Grandis JR
• New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Wang VE, Grandis JR, Ko AH
• Prevention of Carcinogen-Induced Oral Cancer by Sulforaphane.
  Cancer prevention research (Philadelphia, Pa.) 2016 Bauman JE, Zang Y, Sen M, Li C, Wang L, Egner PA, Fahey JW, Normolle DP, Grandis JR, Kensler TW, Johnson DE
• Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors.
  Bioorganic & medicinal chemistry letters 2016 LaPorte MG, Wang Z, Colombo R, Garzan A, Peshkov VA, Liang M, Johnston PA, Schurdak ME, Sen M, Camarco DP, Hua Y, Pollock NI, Lazo JS, Grandis JR, Wipf P, Huryn DM
• STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma.
  Cancer prevention research (Philadelphia, Pa.) 2016 Peyser ND, Wang L, Zeng Y, Acquafondata M, Freilino M, Li H, Sen M, Gooding WE, Satake M, Wang Z, Johnson DE, Grandis JR
• Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma.
  Head & neck 2016 Geiger JL, Bauman JE, Gibson MK, Gooding WE, Varadarajan P, Kotsakis A, Martin D, Gutkind JS, Hedberg ML, Grandis JR, Argiris A
• Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer.
  Annals of oncology : official journal of the European Society for Medical Oncology 2016 Argiris A, Bauman JE, Ohr J, Gooding WE, Heron DE, Duvvuri U, Kubicek GJ, Posluszny DM, Vassilakopoulou M, Kim S, Grandis JR, Johnson JT, Gibson MK, Clump DA, Flaherty JT, Chiosea SI, Branstetter B, …
• The degree of intratumor mutational heterogeneity varies by primary tumor sub-site.
  Oncotarget 2016 Ledgerwood LG, Kumar D, Eterovic AK, Wick J, Chen K, Zhao H, Tazi L, Manna P, Kerley S, Joshi R, Wang L, Chiosea SI, Garnett JD, Tsue TT, Chien J, Mills GB, Grandis JR, Thomas SM
• MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin.
  Oncotarget 2016 Wen Y, Li H, Zeng Y, Wen W, Pendleton KP, Lui VW, Egloff AM, Grandis JR
• Corrigendum to "Cetuximab activity in dysplastic lesions of the upper aerodigestive tract" [Oral Oncol. 53 (2016) 60-66].
  Oral oncology 2016 Khan Z, Epstein JB, Marur S, Boyd Gillespie M, Feldman L, Tsai HL, Zhang Z, Wang H, Sciubba J, Ferris RL, Grandis JR, Gibson M, Koch W, Tufano R, Westra W, Tsottles N, Ozawa H, Chung CH, Califano JA
• Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.
  The Journal of clinical investigation 2016 Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR
• HER2 and HER3 in HPV+ and HPV- HNSCC--Response.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Grandis J
• Oral Cancer Chemoprevention--The End of EPOC, the Beginning of an Epoch of Molecular Selection.
  JAMA oncology 2016 Bauman JE, Grandis J
• A Young Man With Chronic Discharge From the Skin of the Lateral Neck. Thyroglossal duct fistula.
  JAMA otolaryngology-- head & neck surgery 2016 Prabhu AV, Grandis J, Branstetter BF
• The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.
  Oral oncology 2015 Geiger JL, Grandis JR, Bauman JE
• Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts.
  Molecular cancer research : MCR 2015 Li H, Wheeler S, Park Y, Ju Z, Thomas SM, Fichera M, Egloff AM, Lui VW, Duvvuri U, Bauman JE, Mills GB, Grandis JR
• Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.
  Cancer research 2015 Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR, Arteaga CL
• Cetuximab activity in dysplastic lesions of the upper aerodigestive tract.
  Oral oncology 2015 Khan Z, Epstein JB, Marur S, Gillespie MB, Feldman L, Tsai HL, Zhang Z, Wang H, Sciubba J, Ferris R, Grandis JR, Gibson M, Koch W, Tufano R, Westra W, Tsottles N, Ozawa H, Chung C, Califano JA
• Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.
  The Journal of clinical investigation 2015 Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR
• Nucleic acid targeting: towards personalized therapy for head and neck cancer.
  Oncogene 2015 Parsel SM, Grandis JR, Thomas SM
• PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.
  The Journal of clinical investigation 2015 Liao HW, Hsu JM, Xia W, Wang HL, Wang YN, Chang WC, Arold ST, Chou CK, Tsou PH, Yamaguchi H, Fang YF, Lee HJ, Lee HH, Tai SK, Yang MH, Morelli MP, Sen M, Ladbury JE, Chen CH, Grandis JR, Kopetz S, …
• MicroRNA-363 targets myosin 1B to reduce cellular migration in head and neck cancer.
  BMC cancer 2015 Chapman BV, Wald AI, Akhtar P, Munko AC, Xu J, Gibson SP, Grandis JR, Ferris RL, Khan SA
• Ultrasound Targeted Microbubble Destruction-Mediated Delivery of a Transcription Factor Decoy Inhibits STAT3 Signaling and Tumor Growth.
  Theranostics 2015 Kopechek JA, Carson AR, McTiernan CF, Chen X, Hasjim B, Lavery L, Sen M, Grandis JR, Villanueva FS
• HCS campaign to identify selective inhibitors of IL-6-induced STAT3 pathway activation in head and neck cancer cell lines.
  Assay and drug development technologies 2015 Johnston PA, Sen M, Hua Y, Camarco DP, Shun TY, Lazo JS, Wilson GM, Resnick LO, LaPorte MG, Wipf P, Huryn DM, Grandis JR
• HPV-Associated Head and Neck Cancer: Unique Features of Epidemiology and Clinical Management.
  Annual review of medicine 2015 Maxwell JH, Grandis JR, Ferris RL
• Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer.
  PloS one 2015 Peyser ND, Du Y, Li H, Lui V, Xiao X, Chan TA, Grandis JR
• Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Pollock NI, Wang L, Wallweber G, Gooding WE, Huang W, Chenna A, Winslow J, Sen M, DeGrave KA, Li H, Zeng Y, Grandis JR
• Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer.
  Oncogene 2015 Peyser ND, Freilino M, Wang L, Zeng Y, Li H, Johnson DE, Grandis JR
• Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
  JAMA oncology 2015 Van Allen EM, Lui VW, Egloff AM, Goetz EM, Li H, Johnson JT, Duvvuri U, Bauman JE, Stransky N, Zeng Y, Gilbert BR, Pendleton KP, Wang L, Chiosea S, Sougnez C, Wagle N, Zhang F, Du Y, Close D, Johnston…
• Emerging drugs for head and neck cancer.
  Expert opinion on emerging drugs 2015 Wen Y, Grandis JR
• JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
  Neoplasia (New York, N.Y.) 2015 Sen M, Pollock NI, Black J, DeGrave KA, Wheeler S, Freilino ML, Joyce S, Lui VW, Zeng Y, Chiosea SI, Grandis JR
• Challenges in EGFRvIII detection in head and neck squamous cell carcinoma.
  PloS one 2015 Wheeler SE, Egloff AM, Wang L, James CD, Hammerman PS, Grandis JR
• Therapeutic insights from genomic studies of head and neck squamous cell carcinomas.
  Cancer discovery 2015 Hammerman PS, Hayes DN, Grandis JR
• Incidence of head and neck squamous cell carcinoma among subjects at high risk of lung cancer: results from the Pittsburgh Lung Screening Study.
  Cancer 2015 Dixit R, Weissfeld JL, Wilson DO, Balogh P, Sufka P, Siegfried JM, Grandis JR, Diergaarde B
• Identification of epidermal growth factor receptor (EGFR) genetic variants that modify risk for head and neck squamous cell carcinoma.
  Cancer letters 2014 Fung C, Zhou P, Joyce S, Trent K, Yuan JM, Grandis JR, Weissfeld JL, Romkes M, Weeks DE, Egloff AM
• HER2 as a therapeutic target in head and neck squamous cell carcinoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Pollock NI, Grandis JR
• Receptor-type protein tyrosine phosphatases in cancer.
  Chinese journal of cancer 2014 Du Y, Grandis JR
• 2-Guanidinoquinazolines as new inhibitors of the STAT3 pathway.
  Bioorganic & medicinal chemistry letters 2014 LaPorte MG, da Paz Lima DJ, Zhang F, Sen M, Grandis JR, Camarco D, Hua Y, Johnston PA, Lazo JS, Resnick LO, Wipf P, Huryn DM
• Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Egloff AM, Lee JW, Langer CJ, Quon H, Vaezi A, Grandis JR, Seethala RR, Wang L, Shin DM, Argiris A, Yang D, Mehra R, Ridge JA, Patel UA, Burtness BA, Forastiere AA
• EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.
  The Journal of clinical investigation 2014 Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, Nagane M, Su AJ, Auron PE, Hedberg ML, Wang L, Raizer JJ, Kessler JA, Parsa AT, Gao WQ, Kim SH, Minata M, Nakano I, Grandis JR, McLendon RE…
• Identifying and quantifying heterogeneity in high content analysis: application of heterogeneity indices to drug discovery.
  PloS one 2014 Gough AH, Chen N, Shun TY, Lezon TR, Boltz RC, Reese CE, Wagner J, Vernetti LA, Grandis JR, Lee AV, Stern AM, Schurdak ME, Taylor DL
• To "grow" or "go": TMEM16A expression as a switch between tumor growth and metastasis in SCCHN.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Shiwarski DJ, Shao C, Bill A, Kim J, Xiao D, Bertrand CA, Seethala RS, Sano D, Myers JN, Ha P, Grandis J, Gaither LA, Puthenveedu MA, Duvvuri U
• Targeting secondary immune responses to cetuximab: CD137 and the outside story.
  The Journal of clinical investigation 2014 Bauman JE, Grandis JR
• Caspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth.
  Molecular oncology 2014 Li C, Egloff AM, Sen M, Grandis JR, Johnson DE
• Epidemiology of head and neck squamous cell cancer among HIV-infected patients.
  Journal of acquired immune deficiency syndromes (1999) 2014 D'souza G, Carey TE, William WN, Nguyen ML, Ko EC, Riddell J, Pai SI, Gupta V, Walline HM, Lee JJ, Wolf GT, Shin DM, Grandis JR, Ferris RL
• Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Gross ND, Bauman JE, Gooding WE, Denq W, Thomas SM, Wang L, Chiosea S, Hood BL, Flint MS, Sun M, Conrads TP, Ferris RL, Johnson JT, Kim S, Argiris A, Wirth L, Nikiforova MN, Siegfried JM, Grandis JR
• Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects.
  Molecular medicine (Cambridge, Mass.) 2014 Sen M, Paul K, Freilino ML, Li H, Li C, Johnson DE, Wang L, Eiseman J, Grandis JR
• Identification of mutations in the PYRIN-containing NLR genes (NLRP) in Head and Neck Squamous Cell Carcinoma.
  PloS one 2014 Lei Y, Lui VW, Grandis JR, Egloff AM
• Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection.
  Molecular cancer research : MCR 2014 Li H, Wawrose JS, Gooding WE, Garraway LA, Lui VW, Peyser ND, Grandis JR
• Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer.
  Proceedings of the National Academy of Sciences of the United States of America 2014 Lui VW, Peyser ND, Ng PK, Hritz J, Zeng Y, Lu Y, Li H, Wang L, Gilbert BR, General IJ, Bahar I, Ju Z, Wang Z, Pendleton KP, Xiao X, Du Y, Vries JK, Hammerman PS, Garraway LA, Mills GB, Johnson DE, …
• STAT3 oligonucleotide inhibits tumor angiogenesis in preclinical models of squamous cell carcinoma.
  PloS one 2014 Klein JD, Sano D, Sen M, Myers JN, Grandis JR, Kim S
• Genetic mutations in head and neck cancer: utilizing existing treatments.
  Pharmacogenomics 2014 Peyser ND, Grandis JR
• PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma.
  BMC cancer 2013 Chiosea SI, Grandis JR, Lui VW, Diergaarde B, Maxwell JH, Ferris RL, Kim SW, Luvison A, Miller M, Nikiforova MN
• Integration of molecular targeted therapy with radiation in head and neck cancer.
  Pharmacology & therapeutics 2013 Du Y, Peyser ND, Grandis JR
• Collagen type XI α1 facilitates head and neck squamous cell cancer growth and invasion.
  British journal of cancer 2013 Sok JC, Lee JA, Dasari S, Joyce S, Contrucci SC, Egloff AM, Trevelline BK, Joshi R, Kumari N, Grandis JR, Thomas SM
• Single-agent obatoclax (GX15-070) potently induces apoptosis and pro-survival autophagy in head and neck squamous cell carcinoma cells.
  Oral oncology 2013 Yazbeck VY, Li C, Grandis JR, Zang Y, Johnson DE
• High-content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines.
  Assay and drug development technologies 2013 Johnston PA, Sen M, Hua Y, Camarco D, Shun TY, Lazo JS, Grandis JR
• Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study.
  Cancer prevention research (Philadelphia, Pa.) 2013 Saba NF, Hurwitz SJ, Kono SA, Yang CS, Zhao Y, Chen Z, Sica G, Müller S, Moreno-Williams R, Lewis M, Grist W, Chen AY, Moore CE, Owonikoko TK, Ramalingam S, Beitler JJ, Nannapaneni S, Shin HJ, Grandis…
• Critical analysis of the potential for targeting STAT3 in human malignancy.
  OncoTargets and therapy 2013 Peyser ND, Grandis JR
• Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer.
  Oncogene 2013 Panupinthu N, Yu S, Zhang D, Zhang F, Gagea M, Lu Y, Grandis JR, Dunn SE, Lee HY, Mills GB
• Expression of EGFR, VEGF, and NOTCH1 suggest differences in tumor angiogenesis in HPV-positive and HPV-negative head and neck squamous cell carcinoma.
  Head and neck pathology 2013 Troy JD, Weissfeld JL, Youk AO, Thomas S, Wang L, Grandis JR
• Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.
  Cancer discovery 2013 Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q, Du Y, Gilbert BR, Freilino M, Sauerwein S, Peyser ND, Xiao D, Diergaarde B, Wang L, Chiosea S, Seethala R, Johnson JT, Kim S, …
• Childhood passive smoke exposure is associated with adult head and neck cancer.
  Cancer epidemiology 2013 Troy JD, Grandis JR, Youk AO, Diergaarde B, Romkes M, Weissfeld JL
• Polymorphisms in NAT2 and GSTP1 are associated with survival in oral and oropharyngeal cancer.
  Cancer epidemiology 2013 Troy JD, Weissfeld JL, Diergaarde B, Youk AO, Buch SC, Romkes M, Grandis JR
• Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Shin DM, Zhang H, Saba NF, Chen AY, Nannapaneni S, Amin AR, Müller S, Lewis M, Sica G, Kono S, Brandes JC, Grist WJ, Moreno-Williams R, Beitler JJ, Thomas SM, Chen Z, Shin HJ, Grandis JR, Khuri FR, …
• The Fanconi anemia pathway: repairing the link between DNA damage and squamous cell carcinoma.
  Mutation research 2013 Romick-Rosendale LE, Lui VWY, Grandis JR, Wells SI
• Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma.
  American journal of nuclear medicine and molecular imaging 2013 Mason NS, Lopresti BJ, Ruszkiewicz J, Dong X, Joyce S, Leef G, Sen M, Wahed AS, Mathis CA, Grandis JR, Thomas SM
• Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck.
  Clinical medicine insights. Therapeutics 2013 Pendleton KP, Grandis JR
• c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Stabile LP, He G, Lui VW, Thomas S, Henry C, Gubish CT, Joyce S, Quesnelle KM, Siegfried JM, Grandis JR
• Antitumor effects of EGFR antisense guanidine-based peptide nucleic acids in cancer models.
  ACS chemical biology 2012 Thomas SM, Sahu B, Rapireddy S, Bahal R, Wheeler SE, Procopio EM, Kim J, Joyce SC, Contrucci S, Wang Y, Chiosea SI, Lathrop KL, Watkins S, Grandis JR, Armitage BA, Ly DH
• Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.
  Neoplasia (New York, N.Y.) 2012 Cassell A, Freilino ML, Lee J, Barr S, Wang L, Panahandeh MC, Thomas SM, Grandis JR
• Nucleic acid-based approaches to STAT inhibition.
  JAK-STAT 2012 Sen M, Grandis JR
• The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.
  Autophagy 2012 Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE
• EGFR tyrosine kinase inhibition induces autophagy in cancer cells.
  Cancer biology & therapy 2012 Fung C, Chen X, Grandis JR, Duvvuri U
• Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE
• Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.
  Annals of oncology : official journal of the European Society for Medical Oncology 2012 Argiris A, Kotsakis AP, Hoang T, Worden FP, Savvides P, Gibson MK, Gyanchandani R, Blumenschein GR, Chen HX, Grandis JR, Harari PM, Kies MS, Kim S
• Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
  Cancer biology & therapy 2012 Quesnelle KM, Wheeler SE, Ratay MK, Grandis JR
• Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Sen M, Joyce S, Panahandeh M, Li C, Thomas SM, Maxwell J, Wang L, Gooding WE, Johnson DE, Grandis JR
• Molecular pathways: context-dependent approaches to Notch targeting as cancer therapy.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Egloff AM, Grandis JR
• Primary chemotherapy and radiation as a treatment strategy for HPV-positive oropharyngeal cancer.
  Head and neck pathology 2012 Lui VW, Grandis JR
• Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer.
  Oral oncology 2012 Moskowitz HS, Gooding WE, Thomas SM, Freilino ML, Gross N, Argiris A, Grandis JR, Ferris RL
• First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy.
  Cancer discovery 2012 Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, Johnson JT, Duvvuri U, Lee J, Sahu N, Joyce S, Freilino ML, Shi H, Li C, Ly D, Rapireddy S, Etter JP, Li PK, Wang L, Chiosea S, Seethala RR, Gooding WE, …
• TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression.
  Cancer research 2012 Duvvuri U, Shiwarski DJ, Xiao D, Bertrand C, Huang X, Edinger RS, Rock JR, Harfe BD, Henson BJ, Kunzelmann K, Schreiber R, Seethala RS, Egloff AM, Chen X, Lui VW, Grandis JR, Gollin SM
• Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Wheeler SE, Morariu EM, Bednash JS, Otte CG, Seethala RR, Chiosea SI, Grandis JR
• Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer.
  Molecular cancer therapeutics 2012 Bhola NE, Freilino ML, Joyce SC, Sen M, Thomas SM, Sahu A, Cassell A, Chen CS, Grandis JR
• Elevated gastrin-releasing peptide receptor mRNA expression in buccal mucosa: association with head and neck squamous cell carcinoma.
  Head & neck 2012 Egloff AM, Liu X, Davis AL, Trevelline BK, Vuga M, Siegfried JM, Grandis JR
• Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Wheeler S, Siwak DR, Chai R, LaValle C, Seethala RR, Wang L, Cieply K, Sherer C, Joy C, Mills GB, Argiris A, Siegfried JM, Grandis JR, Egloff AM
• Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma.
  Head & neck 2012 Klein JD, Christopoulos A, Ahn SM, Gooding WE, Grandis JR, Kim S
• Gastrin-releasing peptide receptor expression in non-cancerous bronchial epithelia is associated with lung cancer: a case-control study.
  Respiratory research 2012 Egloff AM, Gaither Davis A, Shuai Y, Land S, Pilewski JM, Luketich JD, Landreneau R, Miller YE, Grandis JR, Siegfried JM
• Screening for head and neck cancer in liver transplant candidates: a review of 11 years of experience at the University of Pittsburgh.
  The Laryngoscope 2011 Dedhia RC, Grandis JR, Fontes PA, Johnson JT, Weissfeld J
• Effects of ERCC2 Lys751Gln (A35931C) and CCND1 (G870A) polymorphism on outcome of advanced-stage squamous cell carcinoma of the head and neck are treatment dependent.
  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2011 Zhong S, Nukui T, Buch S, Diergaarde B, Weissfeld LA, Grandis J, Romkes M, Weissfeld JL
• Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies.
  Investigational new drugs 2011 Argiris A, Feinstein TM, Wang L, Yang T, Agrawal S, Appleman LJ, Stoller RG, Grandis JR, Egloff AM
• Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer.
  Oral oncology 2011 Argiris A, Lee SC, Feinstein T, Thomas S, Branstetter BF, Seethala R, Wang L, Gooding W, Grandis JR, Ferris RL
• Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Zhao M, Sano D, Pickering CR, Jasser SA, Henderson YC, Clayman GL, Sturgis EM, Ow TJ, Lotan R, Carey TE, Sacks PG, Grandis JR, Sidransky D, Heldin NE, Myers JN
• Targeting mesenchymal exaptation to mitigate tumor growth.
  Cell cycle (Georgetown, Tex.) 2011 Thomas SM, Grandis JR
• New advances in molecular approaches to head and neck squamous cell carcinoma.
  Anti-cancer drugs 2011 Sahu N, Grandis JR
• The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy.
  American journal of clinical oncology 2011 Rwigema JC, Heron DE, Ferris RL, Andrade RS, Gibson MK, Yang Y, Ozhasoglu C, Argiris AE, Grandis JR, Burton SA
• The mutational landscape of head and neck squamous cell carcinoma.
  Science (New York, N.Y.) 2011 Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortés ML, Auclair D, Berger …
• Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Quesnelle KM, Grandis JR
• Female hormonal and reproductive factors and head and neck squamous cell carcinoma risk.
  Cancer letters 2011 Langevin SM, Grandis JR, Taioli E
• Radiation Resistance in Cancer Therapy: Meeting Summary and Research Opportunities: Report of an NCI Workshop held September 1-3, 2010.
  Radiation research 2011 Glazer PM, Grandis J, Powell SN, Brown JM, Helleday T, Bristow R, Powis G, Hill RP, Le QT, Pelroy R, Mohla S, Bernhard EJ
• Radiation Resistance in Cancer Therapy: meeting summary and research opportunities. Report of an NCI Workshop held September 1-3, 2010.
  Radiation research 2011 Glazer PM, Grandis J, Powell SN, Brown JM, Helleday T, Bristow R, Powis G, Hill RP, Le QT, Pelroy R, Mohla S, Bernhard EJ, NCI Workshop Participants
• XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Vaezi A, Wang X, Buch S, Gooding W, Wang L, Seethala RR, Weaver DT, D'Andrea AD, Argiris A, Romkes M, Niedernhofer LJ, Grandis JR
• Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Bhola NE, Thomas SM, Freilino M, Joyce S, Sahu A, Maxwell J, Argiris A, Seethala R, Grandis JR
• Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, Siegfried JM
• Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer.
  Annals of oncology : official journal of the European Society for Medical Oncology 2011 Argiris A, Karamouzis MV, Smith R, Kotsakis A, Gibson MK, Lai SY, Kim S, Branstetter BF, Shuai Y, Romkes M, Wang L, Grandis JR, Ferris RL, Johnson JT, Heron DE
• Sequential activation of inflammatory signaling pathways during graft-versus-host disease (GVHD): early role for STAT1 and STAT3.
  Cellular immunology 2011 Ma HH, Ziegler J, Li C, Sepulveda A, Bedeir A, Grandis J, Lentzsch S, Mapara MY
• STAT3 signaling: anticancer strategies and challenges.
  Molecular interventions 2011 Johnston PA, Grandis JR
• Prognostic factors in patients with high-risk locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy.
  Head & neck 2011 Feinstein TM, Lai SY, Lenzner D, Gooding W, Ferris RL, Grandis JR, Myers EN, Johnson JT, Heron DE, Argiris A
• Response to combined molecular targeting: defining the role of P-STAT3.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Egloff AM, Grandis JR
• Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma.
  Cancer prevention research (Philadelphia, Pa.) 2010 Leeman-Neill RJ, Seethala RR, Singh SV, Freilino ML, Bednash JS, Thomas SM, Panahandeh MC, Gooding WE, Joyce SC, Lingen MW, Neill DB, Grandis JR
• Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Argiris A, Heron DE, Smith RP, Kim S, Gibson MK, Lai SY, Branstetter BF, Posluszny DM, Wang L, Seethala RR, Dacic S, Gooding W, Grandis JR, Johnson JT, Ferris RL
• Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Stabile LP, Dacic S, Land SR, Lenzner DE, Dhir R, Acquafondata M, Landreneau RJ, Grandis JR, Siegfried JM
• MicroRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck.
  Cancer 2010 Langevin SM, Stone RA, Bunker CH, Lyons-Weiler MA, LaFramboise WA, Kelly L, Seethala RR, Grandis JR, Sobol RW, Taioli E
• Determinants of head and neck cancer survival by race.
  Head & neck 2010 Ragin CC, Langevin SM, Marzouk M, Grandis J, Taioli E
• Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck.
  Head & neck 2010 Sharafinski ME, Ferris RL, Ferrone S, Grandis JR
• Emerging drugs to treat squamous cell carcinomas of the head and neck.
  Expert opinion on emerging drugs 2010 Fung C, Grandis JR
• Human papillomavirus and head and neck cancer.
  Oncology (Williston Park, N.Y.) 2010 Diergaarde B, Grandis JR
• Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation.
  Oncogene 2010 Wheeler SE, Suzuki S, Thomas SM, Sen M, Leeman-Neill RJ, Chiosea SI, Kuan CT, Bigner DD, Gooding WE, Lai SY, Grandis JR
• Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Ostrow KL, Hoque MO, Loyo M, Brait M, Greenberg A, Siegfried JM, Grandis JR, Gaither Davis A, Bigbee WL, Rom W, Sidransky D
• Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer.
  Cancer prevention research (Philadelphia, Pa.) 2010 Taoudi Benchekroun M, Saintigny P, Thomas SM, El-Naggar AK, Papadimitrakopoulou V, Ren H, Lang W, Fan YH, Huang J, Feng L, Lee JJ, Kim ES, Hong WK, Johnson FM, Grandis JR, Mao L
• Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer.
  Journal of proteome research 2010 Yang W, Cai Q, Lui VW, Everley PA, Kim J, Bhola N, Quesnelle KM, Zetter BR, Steen H, Freeman MR, Grandis JR
• Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma.
  Expert opinion on investigational drugs 2010 Cassell A, Grandis JR
• Response assessment by combined PET-CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy.
  Annals of oncology : official journal of the European Society for Medical Oncology 2010 Passero VA, Branstetter BF, Shuai Y, Heron DE, Gibson MK, Lai SY, Kim SW, Grandis JR, Ferris RL, Johnson JT, Argiris A
• New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Chen LF, Cohen EE, Grandis JR
• Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Leeman-Neill RJ, Cai Q, Joyce SC, Thomas SM, Bhola NE, Neill DB, Arbiser JL, Grandis JR
• Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Pectasides E, Egloff AM, Sasaki C, Kountourakis P, Burtness B, Fountzilas G, Dafni U, Zaramboukas T, Rampias T, Rimm D, Grandis J, Psyrri A
• MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index.
  Carcinogenesis 2010 Langevin SM, Stone RA, Bunker CH, Grandis JR, Sobol RW, Taioli E
• The impact of health insurance status on the survival of patients with head and neck cancer.
  Cancer 2010 Kwok J, Langevin SM, Argiris A, Grandis JR, Gooding WE, Taioli E
• The molecular pathogenesis of head and neck cancer.
  Cancer biology & therapy 2010 Klein JD, Grandis JR
• Management of patients treated with chemoradiotherapy for head and neck cancer without prophylactic feeding tubes: the University of Pittsburgh experience.
  The Laryngoscope 2010 McLaughlin BT, Gokhale AS, Shuai Y, Diacopoulos J, Carrau R, Heron DE, Smith RP, Gibson MK, Ferris RL, Grandis JR, Johnson JT, Argiris A
• Molecular changes in the multistage pathogenesis of head and neck cancer.
  Cancer biomarkers : section A of Disease markers 2010 Park BJ, Chiosea SI, Grandis JR
• Systematic prediction of human membrane receptor interactions.
  Proteomics 2009 Qi Y, Dhiman HK, Bhola N, Budyak I, Kar S, Man D, Dutta A, Tirupula K, Carr BI, Grandis J, Bar-Joseph Z, Klein-Seetharaman J
• The current state of head and neck cancer gene therapy.
  Human gene therapy 2009 Thomas SM, Grandis JR
• An informatics supported web-based data annotation and query tool to expedite translational research for head and neck malignancies.
  BMC cancer 2009 Amin W, Kang HP, Egloff AM, Singh H, Trent K, Ridge-Hetrick J, Seethala RR, Grandis J, Parwani AV
• STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro.
  International journal of cancer 2009 Lui VW, Wong EY, Ho Y, Hong B, Wong SC, Tao Q, Choi GC, Au TC, Ho K, Yau DM, Ma BB, Hui EP, Chan AS, Tsang CM, Tsao SW, Grandis JR, Chan AT
• Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Egloff AM, Rothstein ME, Seethala R, Siegfried JM, Grandis JR, Stabile LP
• Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3.
  Carcinogenesis 2009 Leeman-Neill RJ, Wheeler SE, Singh SV, Thomas SM, Seethala RR, Neill DB, Panahandeh MC, Hahm ER, Joyce SC, Sen M, Cai Q, Freilino ML, Li C, Johnson DE, Grandis JR
• Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.
  Molecular cancer therapeutics 2009 Li C, Zang Y, Sen M, Leeman-Neill RJ, Man DS, Grandis JR, Johnson DE
• Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors.
  Journal of oncology 2009 Egloff AM, Grandis JR
• HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, Suzuki S, Quesnelle KM, Morgan S, Ferris RL, Grandis JR, Siegfried JM
• Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial.
  International journal of radiation oncology, biology, physics 2009 Heron DE, Ferris RL, Karamouzis M, Andrade RS, Deeb EL, Burton S, Gooding WE, Branstetter BF, Mountz JM, Johnson JT, Argiris A, Grandis JR, Lai SY
• PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells.
  Oncogene 2009 Sun Q, Ming L, Thomas SM, Wang Y, Chen ZG, Ferris RL, Grandis JR, Zhang L, Yu J
• Targeting angiogenesis from premalignancy to metastases.
  Cancer prevention research (Philadelphia, Pa.) 2009 Grandis JR, Argiris A
• Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells.
  Cancer immunology, immunotherapy : CII 2009 López-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S, Ferris RL
• ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.
  Molecular pharmacology 2009 Li R, Zang Y, Li C, Patel NS, Grandis JR, Johnson DE
• Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Lai SY, Koppikar P, Thomas SM, Childs EE, Egloff AM, Seethala RR, Branstetter BF, Gooding WE, Muthukrishnan A, Mountz JM, Lui VW, Shin DM, Agarwala SS, Johnson R, Couture LA, Myers EN, Johnson JT, …
• Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond.
  Seminars in radiation oncology 2009 Harari PM, Wheeler DL, Grandis JR
• Constitutive activation of signal transducer and activator of transcription 5 contributes to tumor growth, epithelial-mesenchymal transition, and resistance to epidermal growth factor receptor targeting.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Koppikar P, Lui VW, Man D, Xi S, Chai RL, Nelson E, Tobey AB, Grandis JR
• Kinin b2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas.
  Molecular cancer research : MCR 2008 Zhang W, Bhola N, Kalyankrishna S, Gooding W, Hunt J, Seethala R, Grandis JR, Siegfried JM
• Genetic screening for oral human papillomavirus infections and cancers of the head and neck.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Sok JC, Grandis JR
• Human rhomboid family-1 gene RHBDF1 participates in GPCR-mediated transactivation of EGFR growth signals in head and neck squamous cancer cells.
  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2008 Zou H, Thomas SM, Yan ZW, Grandis JR, Vogt A, Li LY
• Lack of toxicity of a STAT3 decoy oligonucleotide.
  Cancer chemotherapy and pharmacology 2008 Sen M, Tosca PJ, Zwayer C, Ryan MJ, Johnson JD, Knostman KA, Giclas PC, Peggins JO, Tomaszewski JE, McMurray TP, Li C, Leibowitz MS, Ferris RL, Gooding WE, Thomas SM, Johnson DE, Grandis JR
• ErbB receptors in the biology and pathology of the aerodigestive tract.
  Experimental cell research 2008 Morgan S, Grandis JR
• Resveratrol causes COX-2- and p53-dependent apoptosis in head and neck squamous cell cancer cells.
  Journal of cellular biochemistry 2008 Lin HY, Sun M, Tang HY, Simone TM, Wu YH, Grandis JR, Cao HJ, Davis PJ, Davis FB
• Combined inhibition of PLC{gamma}-1 and c-Src abrogates epidermal growth factor receptor-mediated head and neck squamous cell carcinoma invasion.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Nozawa H, Howell G, Suzuki S, Zhang Q, Qi Y, Klein-Seetharaman J, Wells A, Grandis JR, Thomas SM
• Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Koppikar P, Choi SH, Egloff AM, Cai Q, Suzuki S, Freilino M, Nozawa H, Thomas SM, Gooding WE, Siegfried JM, Grandis JR
• Human rhomboid family-1 gene silencing causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth.
  Molecular cancer therapeutics 2008 Yan Z, Zou H, Tian F, Grandis JR, Mixson AJ, Lu PY, Li LY
• Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.
  Molecular cancer therapeutics 2008 Li C, Li R, Grandis JR, Johnson DE
• Introduction: head and neck cancer.
  Seminars in oncology 2008 Vokes EE, Cohen EE, Grandis JR
• Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer.
  Seminars in oncology 2008 Egloff AM, Grandis JR
• Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer.
  Head & neck 2008 Kim S, Grandis JR, Rinaldo A, Takes RP, Ferlito A
• Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck.
  Molecular pharmacology 2008 Boehm AL, Sen M, Seethala R, Gooding WE, Freilino M, Wong SM, Wang S, Johnson DE, Grandis JR
• Immunohistochemical analysis of phosphotyrosine signal transducer and activator of transcription 3 and epidermal growth factor receptor autocrine signaling pathways in head and neck cancers and metastatic lymph nodes.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Seethala RR, Gooding WE, Handler PN, Collins B, Zhang Q, Siegfried JM, Grandis JR
• Long-term results of a phase III randomized trial of postoperative radiotherapy with or without carboplatin in patients with high-risk head and neck cancer.
  The Laryngoscope 2008 Argiris A, Karamouzis MV, Johnson JT, Heron DE, Myers E, Eibling D, Cano E, Urba S, Gluckman J, Grandis JR, Wang Y, Agarwala SS
• Gefitinib potentiates myeloid cell differentiation by ATRA.
  Leukemia 2008 Miranda MB, Duan R, Thomas SM, Grandis JR, Redner RL, Jones JE, Johnson DE
• Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer.
  Frontiers in bioscience : a journal and virtual library 2008 Bhola NE, Grandis JR
• Clinical applications of gene therapy in head and neck cancer.
  Current gene therapy 2007 Karamouzis MV, Argiris A, Grandis JR
• Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
  Molecular pharmacology 2007 Thomas SM, Ogagan MJ, Freilino ML, Strychor S, Walsh DR, Gooding WE, Grandis JR, Zamboni WC
• NF-kappaB gene signatures and p53 mutations in head and neck squamous cell carcinoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Ferris RL, Grandis JR
• STAT-mediated EGFR signaling in cancer.
  Journal of cellular biochemistry 2007 Quesnelle KM, Boehm AL, Grandis JR
• Targeting antiapoptotic Bcl-2 family members with cell-permeable BH3 peptides induces apoptosis signaling and death in head and neck squamous cell carcinoma cells.
  Neoplasia (New York, N.Y.) 2007 Li R, Boehm AL, Miranda MB, Shangary S, Grandis JR, Johnson DE
• Advances and challenges in aerodigestive epithelial cancer: meeting summary and research opportunities.
  Cancer research 2007 Grandis JR, Carbone DP, Rustgi AK
• Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
  JAMA 2007 Karamouzis MV, Grandis JR, Argiris A
• Aberrant kinase signaling: lessons from head and neck cancer.
  Future oncology (London, England) 2007 Nelson EG, Grandis JR
• Multiple cytokine and growth factor serum biomarkers predict therapeutic response and survival in advanced-stage head and neck cancer patients.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Bigbee WL, Grandis JR, Siegfried JM
• Association of the EGFR intron 1 CA repeat length with lung cancer risk.
  Molecular carcinogenesis 2007 Zhang W, Weissfeld JL, Romkes M, Land SR, Grandis JR, Siegfried JM
• Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer.
  Molecular cancer therapeutics 2007 Zhang Q, Bhola NE, Lui VW, Siwak DR, Thomas SM, Gubish CT, Siegfried JM, Mills GB, Shin D, Grandis JR
• Altered inflammatory gene expression underlies increased susceptibility to murine postoperative ileus with advancing age.
  American journal of physiology. Gastrointestinal and liver physiology 2007 Moore BA, Albers KM, Davis BM, Grandis JR, Tögel S, Bauer AJ
• Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Fridman JS, Caulder E, Hansbury M, Liu X, Yang G, Wang Q, Lo Y, Zhou BB, Pan M, Thomas SM, Grandis JR, Zhuo J, Yao W, Newton RC, Friedman SM, Scherle PA, Vaddi K
• Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1.
  Molecular pharmacology 2007 Lui VW, Boehm AL, Koppikar P, Leeman RJ, Johnson D, Ogagan M, Childs E, Freilino M, Grandis JR
• Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib.
  Experimental cell research 2007 Liu X, Carlisle DL, Swick MC, Gaither-Davis A, Grandis JR, Siegfried JM
• Head and neck squamous cell carcinoma cell lines: established models and rationale for selection.
  Head & neck 2007 Lin CJ, Grandis JR, Carey TE, Gollin SM, Whiteside TL, Koch WM, Ferris RL, Lai SY
• Established and emerging concepts in epidermal growth factor receptor biology.
  International journal of radiation oncology, biology, physics 2007 Grandis JR
• The role of CD44 in HNSCC.
  Cancer biology & therapy 2007 Nelson AD, Grandis JR
• Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma.
  Cancer research 2006 Thomas SM, Bhola NE, Zhang Q, Contrucci SC, Wentzel AL, Freilino ML, Gooding WE, Siegfried JM, Chan DC, Grandis JR
• Understanding the presence and function of erythropoietin receptors on cancer cells.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006 Lai SY, Grandis JR
• Epidermal growth factor receptor-targeted molecular therapeutics for head and neck squamous cell carcinoma.
  Expert opinion on therapeutic targets 2006 Egloff AM, Grandis J
• Frameless stereotactic radiosurgery for recurrent head and neck carcinoma.
  Technology in cancer research & treatment 2006 Voynov G, Heron DE, Burton S, Grandis J, Quinn A, Ferris R, Ozhasoglu C, Vogel W, Johnson J
• Importance of molecular analysis in detecting cervical lymph node metastasis in head and neck squamous cell carcinoma.
  Head & neck 2006 Elsheikh MN, Rinaldo A, Hamakawa H, Mahfouz ME, Rodrigo JP, Brennan J, Devaney KO, Grandis JR, Ferlito A
• Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR
• Mutation and polymorphism in the EGFR-TK domain associated with lung cancer.
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006 Zhang W, Stabile LP, Keohavong P, Romkes M, Grandis JR, Traynor AM, Siegfried JM
• Prognostic biomarkers in head and neck cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Grandis JR
• Research education and training in otolaryngology: meeting summary and research opportunities.
  Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2006 Grandis JR, Battey JF, Califf RM, Chole RA, Gantz BJ, Gates GA, Gorelic L, Hannley MT, Hardwick KS, Harris JP, Kapoor WN, Lai SY, Lalwani AK, Minor LB, Nadol JP, Post JC, Roland PS, Schechter AM, …
• STAT3 is required but not sufficient for EGF receptor-mediated migration and invasion of human prostate carcinoma cell lines.
  British journal of cancer 2006 Zhou W, Grandis JR, Wells A
• Epidermal growth factor receptor biology in head and neck cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006 Kalyankrishna S, Grandis JR
• Head and neck cancer: recent advances and new standards of care.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006 Forastiere AA, Trotti A, Pfister DG, Grandis JR
• Women in otolaryngology: closing the gender gap.
  Current opinion in otolaryngology & head and neck surgery 2006 Ferguson BJ, Grandis JR
• Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation.
  Proceedings of the National Academy of Sciences of the United States of America 2006 Zhang Q, Thomas SM, Lui VW, Xi S, Siegfried JM, Fan H, Smithgall TE, Mills GB, Grandis JR
• STAT3 as a therapeutic target in head and neck cancer.
  Expert opinion on biological therapy 2006 Leeman RJ, Lui VW, Grandis JR
• Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis.
  Journal of the National Cancer Institute 2006 Xi S, Dyer KF, Kimak M, Zhang Q, Gooding WE, Chaillet JR, Chai RL, Ferrell RE, Zamboni B, Hunt J, Grandis JR
• Advances in molecular diagnostics and therapeutics in head and neck cancer.
  Current treatment options in oncology 2006 Chai RL, Grandis JR
• Inhibition of insulin/IGF-1 receptor signaling enhances bile acid toxicity in primary hepatocytes.
  Biochemical pharmacology 2005 Dent P, Han SI, Mitchell C, Studer E, Yacoub A, Grandis J, Grant S, Krystal GW, Hylemon PB
• Role of NQO1 polymorphisms as risk factors for squamous cell carcinoma of the head and neck.
  Oral oncology 2005 Begleiter A, Norman A, Leitao D, Cabral T, Hewitt D, Pan S, Grandis JR, Siegfried JM, El-Sayed S, Sutherland D, Ross DA, Kerr PD
• Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR.
  Oncogene 2005 Wang J, Zhang X, Thomas SM, Grandis JR, Wells A, Chen ZG, Ferris RL
• Molecular mediators of metastasis in head and neck squamous cell carcinoma.
  Head & neck 2005 Howell GM, Grandis JR
• Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma.
  Oncogene 2005 Lai SY, Childs EE, Xi S, Coppelli FM, Gooding WE, Wells A, Ferris RL, Grandis JR
• Association of polymorphisms in the cyclin D1 and XPD genes and susceptibility to cancers of the upper aero-digestive tract.
  Molecular carcinogenesis 2005 Buch S, Zhu B, Davis AG, Odom D, Siegfried JM, Grandis JR, Romkes M
• Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells.
  Neoplasia (New York, N.Y.) 2005 Thomas SM, Grandis JR, Wentzel AL, Gooding WE, Lui VW, Siegfried JM
• Multiplexed analysis of serum cytokines as biomarkers in squamous cell carcinoma of the head and neck patients.
  The Laryngoscope 2005 Hathaway B, Landsittel DP, Gooding W, Whiteside TL, Grandis JR, Siegfried JM, Bigbee WL, Ferris RL
• Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
  Cancer research 2005 Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM
• In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy.
  Oncogene 2005 Xi S, Gooding WE, Grandis JR
• Antiangiogenic therapy of head and neck squamous cell carcinoma by vascular endothelial growth factor antisense therapy.
  Advances in oto-rhino-laryngology 2005 Riedel F, Götte K, Hörmann K, Grandis JR
• Oligonucleotides as anticancer agents: from the benchside to the clinic and beyond.
  Current pharmaceutical design 2005 Coppelli FM, Grandis JR
• The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy.
  Seminars in oncology 2004 Pomerantz RG, Grandis JR
• IL-12 receptor-mediated upregulation of FasL in human ovarian carcinoma cells.
  International journal of cancer 2004 Gorelik E, Edwards RP, Feng X, Marrangoni AM, Grandis JR, Drenning SD, Velikokhatnaya L, Kwon JA, Lokshin AE
• Head and neck cancer: meeting summary and research opportunities.
  Cancer research 2004 Grandis JR, Pietenpol JA, Greenberger JS, Pelroy RA, Mohla S
• Abrogation of head and neck squamous cell carcinoma growth by epidermal growth factor receptor ligand fused to pseudomonas exotoxin transforming growth factor alpha-PE38.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2004 Thomas SM, Zeng Q, Epperly MW, Gooding WE, Pastan I, Wang QC, Greenberger J, Grandis JR
• Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis.
  Head & neck 2004 Andrews GA, Xi S, Pomerantz RG, Lin CJ, Gooding WE, Wentzel AL, Wu L, Sidransky D, Grandis JR
• SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells.
  Cancer research 2004 Zhang Q, Thomas SM, Xi S, Smithgall TE, Siegfried JM, Kamens J, Gooding WE, Grandis JR
• Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2004 Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR, Shin DM
• The gender gap in a surgical subspecialty: analysis of career and lifestyle factors.
  Archives of otolaryngology--head & neck surgery 2004 Grandis JR, Gooding WE, Zamboni BA, Wagener MM, Drenning SD, Miller L, Doyle KJ, Mackinnon SE, Wagner RL
• Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation.
  Cancer treatment reviews 2004 Thomas SM, Grandis JR
• Signaling through the epidermal growth factor receptor during the development of malignancy.
  Pharmacology & therapeutics 2004 Grandis JR, Sok JC
• Selective jejunal manipulation causes postoperative pan-enteric inflammation and dysmotility.
  Gastroenterology 2004 Schwarz NT, Kalff JC, Türler A, Speidel N, Grandis JR, Billiar TR, Bauer AJ
• Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Niwa H, Wentzel AL, Li M, Gooding WE, Lui VW, Grandis JR
• Constitutive activation of Stat5b contributes to carcinogenesis in vivo.
  Cancer research 2003 Xi S, Zhang Q, Gooding WE, Smithgall TE, Grandis JR
• Tyrphostin AG 126 inhibits development of postoperative ileus induced by surgical manipulation of murine colon.
  American journal of physiology. Gastrointestinal and liver physiology 2003 Moore BA, Türler A, Pezzone MA, Dyer K, Grandis J, Bauer AJ
• Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor.
  Oncogene 2003 Lui VW, Thomas SM, Zhang Q, Wentzel AL, Siegfried JM, Li JY, Grandis JR
• Responsiveness to the retinoic acid receptor-selective retinoid LGD1550 correlates with abrogation of transforming growth factor alpha/epidermal growth factor receptor autocrine signaling in head and neck squamous carcinoma cells.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Lango M, Wentzel AL, Song JI, Xi S, Johnson DE, Lamph WW, Miller L, Grandis JR
• Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo.
  International journal of oncology 2003 Riedel F, Götte K, Li M, Hörmann K, Grandis JR
• Epidermal growth factor receptor-stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinoma.
  Cancer research 2003 Thomas SM, Coppelli FM, Wells A, Gooding WE, Song J, Kassis J, Drenning SD, Grandis JR
• Requirement of a carbon spacer in benzyl isothiocyanate-mediated cytotoxicity and MAPK activation in head and neck squamous cell carcinoma.
  Carcinogenesis 2003 Lui VW, Wentzel AL, Xiao D, Lew KL, Singh SV, Grandis JR
• Tissue distribution of liposome-mediated epidermal growth factor receptor antisense gene therapy.
  Cancer gene therapy 2003 Thomas SM, Zeng Q, Dyer KF, Suscovich TJ, Kanter PM, Whalen JD, Watkins SF, Grandis JR
• Activation of Stat3 by cell confluence reveals negative regulation of Stat3 by cdk2.
  Oncogene 2003 Steinman RA, Wentzel A, Lu Y, Stehle C, Grandis JR
• Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer.
  Expert review of anticancer therapy 2003 Khalil MY, Grandis JR, Shin DM
• Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck.
  The Journal of biological chemistry 2003 Xi S, Zhang Q, Dyer KF, Lerner EC, Smithgall TE, Gooding WE, Kamens J, Grandis JR
• Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth.
  Proceedings of the National Academy of Sciences of the United States of America 2003 Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, Robbins PD, Gadiparthi S, Burke NA, Watkins SF, Grandis JR
• The role of epidermal growth factor receptor in head and neck squamous cell carcinoma.
  Current oncology reports 2003 Pomerantz RG, Grandis JR
• Differential activation of apoptosis regulatory pathways during monocytic vs granulocytic differentiation: a requirement for Bcl-X(L)and XIAP in the prolonged survival of monocytic cells.
  Leukemia 2003 Miranda MB, Dyer KF, Grandis JR, Johnson DE
• Gene therapy for the treatment of oral squamous cell carcinoma.
  Journal of dental research 2003 Xi S, Grandis JR
• Phospholipase C-gamma1 in tumor progression.
  Clinical & experimental metastasis 2003 Wells A, Grandis JR
• Targeting epidermal growth factor receptor in head and neck cancer.
  Head & neck 2003 Ford AC, Grandis JR
• Lipopolysaccharide preconditioning and cross-tolerance: the induction of protective mechanisms for rat intestinal ileus.
  Gastroenterology 2002 Schwarz NT, Engel B, Eskandari MK, Kalff JC, Grandis JR, Bauer AJ
• Stat3 activation in prostatic carcinomas.
  The Prostate 2002 Dhir R, Ni Z, Lou W, DeMiguel F, Grandis JR, Gao AC
• Selective activation of members of the signal transducers and activators of transcription family in prostate carcinoma.
  The Journal of urology 2002 Ni Z, Lou W, Lee SO, Dhir R, DeMiguel F, Grandis JR, Gao AC
• Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck.
  Journal of the National Cancer Institute 2002 Lango MN, Dyer KF, Lui VW, Gooding WE, Gubish C, Siegfried JM, Grandis JR
• EGFR-mediated cell cycle regulation.
  Anticancer research 2002 Lui VW, Grandis JR
• Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma.
  Archives of otolaryngology--head & neck surgery 2001 Fan CY, Melhem MF, Hosal AS, Grandis JR, Barnes EL
• Targeting growth factor receptors: integration of novel therapeutics in the management of head and neck cancer.
  Current opinion in oncology 2001 Lango MN, Shin DM, Grandis JR
• Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2000 Grandis JR, Falkner DM, Melhem MF, Gooding WE, Drenning SD, Morel PA
• Determination of intermediate biomarker expression levels by quantitative reverse transcription-polymerase chain reaction in oral mucosa of cancer patients treated with liarozole.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2000 Zeng Q, Smith DC, Suscovich TJ, Gooding WE, Trump DL, Grandis JR
• STAT signaling in head and neck cancer.
  Oncogene 2000 Song JI, Grandis JR
• Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo.
  Proceedings of the National Academy of Sciences of the United States of America 2000 Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, Johnson DE, Huang L, He Y, Kim JD
• Endoscopic sphenopalatine artery ligation is an effective method of treatment for posterior epistaxis.
  American journal of rhinology 1999 Snyderman CH, Goldman SA, Carrau RL, Ferguson BJ, Grandis JR
• Bcl-2 but not Bax expression is associated with apoptosis in normal and transformed squamous epithelium.
  Clinical cancer research : an official journal of the American Association for Cancer Research 1998 Drenning SD, Marcovitch AJ, Johnson DE, Melhem MF, Tweardy DJ, Grandis JR
• Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro.
  The Journal of clinical investigation 1998 Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, Tweardy DJ
• Growth and differentiation of rat hepatocytes: changes in transcription factors HNF-3, HNF-4, STAT-3, and STAT-5.
  Biochemical and biophysical research communications 1998 Runge D, Runge DM, Drenning SD, Bowen WC, Grandis JR, Michalopoulos GK
• Normalization of EGFR mRNA levels following restoration of wild-type p53 in a head and neck squamous cell carcinoma cell line.
  International journal of oncology 1998 Grandis JR, Zeng Q, Drenning SD, Tweardy DJ
• Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter.
  Journal of the National Cancer Institute 1998 He Y, Zeng Q, Drenning SD, Melhem MF, Tweardy DJ, Huang L, Grandis JR
• Subglottic injury, gastric juice, corticosteroids, and peptide growth factors in a porcine model.
  The Laryngoscope 1998 Yellon RF, Szeremeta W, Grandis JR, Diguisseppe P, Dickman PS
• Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells.
  Journal of cellular biochemistry 1998 Grandis JR, Chakraborty A, Zeng Q, Melhem MF, Tweardy DJ
• Tumor Board Conference from the University of Pittsburgh.
  Oncology (Williston Park, N.Y.) 1997 Pitman KT, Agarwala SS, Cano ER, Eibling DE, Fagan JJ, Grandis JR, Johnson JT, Myers EN, Russavage JM, Snyderman CH, Weismann JL
• Lack of serologic evidence for Helicobacter pylori infection in head and neck cancer.
  Head & neck 1997 Grandis JR, Perez-Perez GI, Yu VL, Johnson JT, Blaser MJ
• Role of subglottic injury, gastric juice, and peptide growth factors in a porcine model.
  International anesthesiology clinics 1997 Yellon RF, Szeremeta W, Grandis JR, Diguisseppe P, Dickman PS
• Necrotizing (malignant) external otitis: prospective comparison of CT and MR imaging in diagnosis and follow-up.
  Radiology 1995 Grandis JR, Curtin HD, Yu VL
• Antitumor activity of interleukin-1 alpha and cisplatin in a murine model system.
  Archives of otolaryngology--head & neck surgery 1995 Grandis JR, Chang MJ, Yu WD, Johnson CS
• Efficacy of topical amoxicillin plus clavulanate/ticarcillin plus clavulanate and clindamycin in contaminated head and neck surgery: effect of antibiotic spectra and duration of therapy.
  The Journal of infectious diseases 1994 Grandis JR, Vickers RM, Rihs JD, Yu VL, Johnson JT
• The efficacy of topical antibiotic prophylaxis for contaminated head and neck surgery.
  The Laryngoscope 1994 Grandis JR, Vickers RM, Rihs JD, Yu VL, Wagner RL, Kachman KK, Johnson JT
• Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer.
  Cancer research 1993 Grandis JR, Tweardy DJ
• Simultaneous presentation of malignant external otitis and temporal bone cancer.
  Archives of otolaryngology--head & neck surgery 1993 Grandis JR, Hirsch BE, Yu VL
• Treatment of idiopathic sudden sensorineural hearing loss.
  The American journal of otology 1993 Grandis JR, Hirsch BE, Wagener MM
• Head and neck cancer.
  Archives of otolaryngology--head & neck surgery 1993 Snyderman CH, Grandis JR, Johnson JT
• Synergistic enhancement by interleukin-1 alpha of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ mice.
  Cancer chemotherapy and pharmacology 1993 Johnson CS, Chang MJ, Yu WD, Modzelewski RA, Grandis JR, Vlock DR, Furmanski P
• TGF-alpha and EGFR in head and neck cancer.
  Journal of cellular biochemistry. Supplement 1993 Grandis JR, Tweardy DJ
• Postoperative wound infection. A poor prognostic sign for patients with head and neck cancer.
  Cancer 1992 Grandis JR, Snyderman CH, Johnson JT, Yu VL, D'Amico F
• The role of peptide growth factors in head and neck carcinoma.
  Otolaryngologic clinics of North America 1992 Grandis JR, Tweardy DJ
• The efficacy of perioperative antibiotic therapy on recovery following tonsillectomy in adults: randomized double-blind placebo-controlled trial.
  Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 1992 Grandis JR, Johnson JT, Vickers RM, Yu VL, Wagener MM, Wagner RL, Kachman KA
• Stomal recurrence after laryngectomy: interrelated risk factor study.
  Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 1990 Rubin J, Johnson JT, Myers EN
• Extramedullary plasmacytoma of the thyroid associated with a serum monoclonal gammopathy.
  Archives of otolaryngology--head & neck surgery 1990 Rubin J, Johnson JT, Killeen R, Barnes L
• Aural irrigation with water: a potential pathogenic mechanism for inducing malignant external otitis?
  The Annals of otology, rhinology, and laryngology 1990 Rubin J, Yu VL, Kamerer DB, Wagener M
• Malignant external otitis: utility of CT in diagnosis and follow-up.
  Radiology 1990 Rubin J, Curtin HD, Yu VL, Kamerer DB
• Efficacy of oral ciprofloxacin plus rifampin for treatment of malignant external otitis.
  Archives of otolaryngology--head & neck surgery 1989 Rubin J, Stoehr G, Yu VL, Muder RR, Matador A, Kamerer DB
• Malignant external otitis in children.
  The Journal of pediatrics 1988 Rubin J, Yu VL, Stool SE
• Bacteriologic analysis of wound infection following major head and neck surgery.
  Archives of otolaryngology--head & neck surgery 1988 Rubin J, Johnson JT, Wagner RL, Yu VL
• Malignant external otitis: insights into pathogenesis, clinical manifestations, diagnosis, and therapy.
  The American journal of medicine 1988 Rubin J, Yu VL